Formycon AG
XETRA:FYB

Watchlist Manager
Formycon AG Logo
Formycon AG
XETRA:FYB
Watchlist
Price: 24.05 EUR -0.62% Market Closed
Market Cap: 425m EUR
Section:
 

Relative Value

The Relative Value of one FYB stock under the Base Case scenario is 62.58 EUR. Compared to the current market price of 24.05 EUR, Formycon AG is Undervalued by 62%.

Relative Value is the estimated value of a stock based on various valuation multiples like P/E and EV/EBIT ratios. It offers a quick snapshot of a stock's valuation in relation to its peers and historical norms.

FYB Relative Value
Base Case
62.58 EUR
Undervaluation 62%
Relative Value
Price
Worst Case
Base Case
Best Case

Valuation Multiples

8.2
P/S
P/S
Price to Sales
8.2
vs History
87
vs Industry
50
Median 3Y
13.6
Median 5Y
14.8
Industry
8.1
Forward
7.7
More Details
Negative
P/E
P/E
Price to Earnings
N/A
vs History
vs Industry
11
Median 3Y
-2.3
Median 5Y
-3
Industry
23.7
Forward
-13.5
More Details
28.8
P/OCF
P/OCF
Price to OCF
28.8
vs History
6
vs Industry
Median 3Y
-40.8
Median 5Y
-54.7
Industry
22.6
More Details
Negative
P/FCFE
P/FCFE
Price to FCFE
N/A
vs History
vs Industry
Median 3Y
-18.1
Median 5Y
-24.3
Industry
25.7
More Details
1
P/B
P/B
Price to Book Value
1
vs History
87
vs Industry
64
Median 3Y
1.6
Median 5Y
2.5
Industry
3.3
More Details
7.8
EV/S
EV/S
Enterprise Value to Sales
7.8
vs History
85
vs Industry
42
Median 3Y
13.1
Median 5Y
14.1
Industry
8.4
Forward
7.4
More Details
Negative
EV/GP
EV/GP
Enterprise Value to Gross Profit
N/A
vs History
vs Industry
13
Median 3Y
38.6
Median 5Y
70.6
Industry
10.4
More Details
3.5
EV/EBITDA
EV/EBITDA
Enterprise Value to EBITDA
3.5
vs History
20
vs Industry
0
Median 3Y
3.2
Median 5Y
-39.5
Industry
5.9
Forward
-22.3
More Details
Negative
EV/EBIT
EV/EBIT
Enterprise Value to EBIT
N/A
vs History
vs Industry
Median 3Y
-34.4
Median 5Y
-38.8
Industry
6.4
Forward
-12.5
More Details
27.5
EV/OCF
EV/OCF
Enterprise Value to OCF
27.5
vs History
6
vs Industry
Median 3Y
-39.4
Median 5Y
-53.3
Industry
8.2
More Details
Negative
EV/FCFF
EV/FCFF
Enterprise Value to FCFF
N/A
vs History
vs Industry
Median 3Y
-18.4
Median 5Y
-23.6
Industry
6.4
More Details
0.6
EV/IC
EV/IC
Enterprise Value to IC
0.6
vs History
88
vs Industry
64
Median 3Y
1
Median 5Y
1.3
Industry
5.8
More Details

Multiples Across Competitors

FYB Competitors Multiples
Formycon AG Competitors

All Multiples
P/S
P/E
EV/EBITDA
EV/EBIT
All Countries
All Countries
Close
Market Cap P/S P/E EV/EBITDA EV/EBIT
DE
Formycon AG
XETRA:FYB
424.8m EUR 8.2 -2.5 3.5 -11
FR
Pharnext SCA
OTC:PNEXF
6T USD 34 198 755.5 -162 541.6 -197 377.4 -195 125.1
US
Abbvie Inc
NYSE:ABBV
378.8B USD 6.4 161.3 15.7 22.3
US
Amgen Inc
NASDAQ:AMGN
177.8B USD 4.9 25.4 18.3 18.3
US
Gilead Sciences Inc
NASDAQ:GILD
155.1B USD 5.3 19.1 12.9 12.9
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
112.1B USD 9.6 30.5 22.3 23.3
US
Epizyme Inc
F:EPE
94.1B EUR 2 060 -525.7 -572.4 -557.1
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
77.2B USD 5.4 16.9 16 18.2
AU
CSL Ltd
ASX:CSL
85B AUD 3.7 18.9 12.8 15.9
NL
argenx SE
XBRU:ARGX
42.4B EUR 13.7 32.1 55.1 56.6
US
Alnylam Pharmaceuticals Inc
NASDAQ:ALNY
47.3B USD 14.8 1 086.8 146.4 177.6
P/S Multiple
Revenue Growth P/S to Growth
DE
Formycon AG
XETRA:FYB
Average P/S: 3 109 171.6
8.2
25%
0.3
FR
Pharnext SCA
OTC:PNEXF
34 198 755.5
N/A N/A
US
Abbvie Inc
NYSE:ABBV
6.4
9%
0.7
US
Amgen Inc
NASDAQ:AMGN
4.9
5%
1
US
Gilead Sciences Inc
NASDAQ:GILD
5.3
4%
1.3
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
9.6
10%
1
US
E
Epizyme Inc
F:EPE
2 060
N/A N/A
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
5.4
6%
0.9
AU
CSL Ltd
ASX:CSL
3.7
5%
0.7
NL
argenx SE
XBRU:ARGX
13.7
49%
0.3
US
Alnylam Pharmaceuticals Inc
NASDAQ:ALNY
14.8
46%
0.3
P/E Multiple
Earnings Growth PEG
DE
Formycon AG
XETRA:FYB
Average P/E: 173.9
Negative Multiple: -2.5 		N/A N/A
FR
Pharnext SCA
OTC:PNEXF
Negative Multiple: -162 541.6 N/A N/A
US
Abbvie Inc
NYSE:ABBV
161.3
89%
1.8
US
Amgen Inc
NASDAQ:AMGN
25.4
45%
0.6
US
Gilead Sciences Inc
NASDAQ:GILD
19.1
190%
0.1
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
30.5
N/A N/A
US
E
Epizyme Inc
F:EPE
Negative Multiple: -525.7 N/A N/A
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
16.9
10%
1.7
AU
CSL Ltd
ASX:CSL
18.9
11%
1.7
NL
argenx SE
XBRU:ARGX
32.1
40%
0.8
US
Alnylam Pharmaceuticals Inc
NASDAQ:ALNY
1 086.8
N/A N/A
EV/EBITDA Multiple
EBITDA Growth EV/EBITDA to Growth
DE
Formycon AG
XETRA:FYB
Average EV/EBITDA: 33.7
3.5
-17%
N/A
FR
Pharnext SCA
OTC:PNEXF
Negative Multiple: -197 377.4 N/A N/A
US
Abbvie Inc
NYSE:ABBV
15.7
14%
1.1
US
Amgen Inc
NASDAQ:AMGN
18.3
11%
1.7
US
Gilead Sciences Inc
NASDAQ:GILD
12.9
7%
1.8
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
22.3
16%
1.4
US
E
Epizyme Inc
F:EPE
Negative Multiple: -572.4 N/A N/A
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
16
11%
1.5
AU
CSL Ltd
ASX:CSL
12.8
8%
1.6
NL
argenx SE
XBRU:ARGX
55.1
810%
0.1
US
Alnylam Pharmaceuticals Inc
NASDAQ:ALNY
146.4
N/A N/A
EV/EBIT Multiple
EBIT Growth EV/EBIT to Growth
DE
Formycon AG
XETRA:FYB
Average EV/EBIT: 43.1
Negative Multiple: -11 		N/A N/A
FR
Pharnext SCA
OTC:PNEXF
Negative Multiple: -195 125.1 N/A N/A
US
Abbvie Inc
NYSE:ABBV
22.3
30%
0.7
US
Amgen Inc
NASDAQ:AMGN
18.3
20%
0.9
US
Gilead Sciences Inc
NASDAQ:GILD
12.9
12%
1.1
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
23.3
16%
1.5
US
E
Epizyme Inc
F:EPE
Negative Multiple: -557.1 N/A N/A
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
18.2
13%
1.4
AU
CSL Ltd
ASX:CSL
15.9
11%
1.4
NL
argenx SE
XBRU:ARGX
56.6
N/A N/A
US
Alnylam Pharmaceuticals Inc
NASDAQ:ALNY
177.6
N/A N/A

See Also

Summary
FYB intrinsic value, competitors valuation, and company profile.
DCF Valuation
FYB stock valuation using Discount Cash Flow valuation method.
Relative Valuation
FYB stock valuation using valuation multiples.
Wall Street Estimates
FYB price targets and financial estimates made by Wall st analysts.
Profitability Analysis
Detailed analysis of the company's profitability.
Solvency Analysis
Analysis of the financial position and solvency of the company.
Financials
Income Statement, Balance Sheet, Cash Flow Statement.
Discount Rate
FYB stock discount rate: cost of equity and WACC.
Summary
DCF Valuation
Relative Valuation
Wall Street Estimates
Profitability Analysis
Solvency Analysis
Financials
Discount Rate
Discover More
Back to Top
ALPHA SPREAD
Follow us
Join more than 310,300+ value investors using Alpha Spread
Create Free Account
or see our plans & pricing

Company

About Us Careers Pricing Affiliate Program Terms of Service Privacy Policy

Help

What is Intrinsic Value? Help Center Contact Us

Tools

Stock Screener Intrinsic Value Calculator DCF Value Calculator Discount Rate Calculator

Stocks

Most Undervalued Stocks Wide Economic Moat Stocks High Profitability Stocks High Solvency Stocks Most Popular Stocks

© 2026 Alpha Spread Limited. All Rights Reserved.

www.alphaspread.com is not operated by a broker, a dealer, or a registered investment adviser. Under no circumstances does any information posted on www.alphaspread.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute, investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. In no event shall Alpha Spread Limited be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on www.alphaspread.com, or relating to the use of, or inability to use, www.alphaspread.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance.